SynAct Pharma (Sweden) Performance
| SYNACT Stock | 23.60 0.85 3.74% |
The entity has a beta of -0.53, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning SynAct Pharma are expected to decrease at a much lower rate. During the bear market, SynAct Pharma is likely to outperform the market. SynAct Pharma AB right now has a risk of 2.97%. Please validate SynAct Pharma expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to decide if SynAct Pharma will be following its existing price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days SynAct Pharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, SynAct Pharma is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 14.5 M | |
| Total Cashflows From Investing Activities | -6000.00 |
SynAct |
SynAct Pharma Relative Risk vs. Return Landscape
If you would invest 2,290 in SynAct Pharma AB on October 15, 2025 and sell it today you would lose (15.00) from holding SynAct Pharma AB or give up 0.66% of portfolio value over 90 days. SynAct Pharma AB is generating 0.0313% of daily returns and assumes 2.9707% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than SynAct, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SynAct Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for SynAct Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as SynAct Pharma AB, and traders can use it to determine the average amount a SynAct Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0105
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SYNACT |
Estimated Market Risk
| 2.97 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.03 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average SynAct Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of SynAct Pharma by adding SynAct Pharma to a well-diversified portfolio.
SynAct Pharma Fundamentals Growth
SynAct Stock prices reflect investors' perceptions of the future prospects and financial health of SynAct Pharma, and SynAct Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SynAct Stock performance.
| Return On Equity | -1.49 | |||
| Return On Asset | -0.81 | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 31.82 M | |||
| Price To Book | 26.57 X | |||
| EBITDA | (76.62 M) | |||
| Book Value Per Share | 2.82 X | |||
| Cash Flow From Operations | (65 M) | |||
| Total Asset | 38.37 M | |||
About SynAct Pharma Performance
By analyzing SynAct Pharma's fundamental ratios, stakeholders can gain valuable insights into SynAct Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if SynAct Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if SynAct Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Things to note about SynAct Pharma AB performance evaluation
Checking the ongoing alerts about SynAct Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SynAct Pharma AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SynAct Pharma AB has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (76.7 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| SynAct Pharma generates negative cash flow from operations | |
| About 37.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing SynAct Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SynAct Pharma's stock is overvalued or undervalued compared to its peers.
- Examining SynAct Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SynAct Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SynAct Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SynAct Pharma's stock. These opinions can provide insight into SynAct Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for SynAct Stock analysis
When running SynAct Pharma's price analysis, check to measure SynAct Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynAct Pharma is operating at the current time. Most of SynAct Pharma's value examination focuses on studying past and present price action to predict the probability of SynAct Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynAct Pharma's price. Additionally, you may evaluate how the addition of SynAct Pharma to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |